Clinical trial
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
NCT03598998 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
- Lead sponsor
- City of Hope Medical Center
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- February 4, 2019
- Completion date
- February 18, 2027
- Enrollment
- 13 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic large cell lymphoma, nodal peripheral t-cell lymphoma with tfh phenotype, recurrent anaplastic large cell lymphoma, recurrent angioimmunoblastic t-cell lymphoma, recurrent enteropathy-associated t-cell lymphoma, recurrent follicular lymphoma, recurrent hepatosplenic t-cell lymphoma, recurrent mature t- cell and nk-cell non-hodgkin lymphoma, recurrent monomorphic epitheliotropic intestinal t-cell lymphoma, recurrent mycosis fungoides, recurrent peripheral t-cell lymphoma, not otherwise specified, refractory anaplastic large cell lymphoma, refractory angioimmunoblastic t-cell lymphoma, refractory enteropathy-associated t-cell lymphoma, refractory follicular lymphoma, refractory hepatosplenic t-cell lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma, refractory mycosis fungoides, refractory peripheral t-cell lymphoma, not otherwise specified, subcutaneous panniculitis-like t-cell lymphoma